SIC
NMRA icon

Salem Investment Counselors’s Neumora Therapeutics NMRA Stock Holding History

Salem Investment Counselors’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-100
Closed -$1.41K – 1136
2023
Q3 		$1.41K Buy
+100
New +$1.25K ﹤0.01% 1004

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Salem Investment Counselors's NMRA Position: Q4 2023 in Review

Salem Investment Counselors sold out of Neumora Therapeutics (NMRA) in Q4 2023, closing a stake of 100 shares — an estimated $1.41K sold.

Salem Investment Counselors first reported a position in NMRA in Q3 2023 and held it in 1 quarter. The position peaked at $1.41K in Q3 2023. 60 funds tracked by Wall St. Rank hold NMRA as of Q4 2023.

  • Salem Investment Counselors reported no remaining Neumora Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Salem Investment Counselors sold 100 Neumora Therapeutics shares in Q4 2023, an estimated $1.41K.
  • Salem Investment Counselors first reported a position in Neumora Therapeutics in Q3 2023 and held it in 1 quarter.
  • Salem Investment Counselors's Neumora Therapeutics position peaked at $1.41K in Q3 2023.
  • 60 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q4 2023.

Based on Salem Investment Counselors's 13F filing for Q4 2023, filed 16 Jan 2024.